Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.11.18 (MAP)
 7,412 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate the effect of a progestinic-estrogenic combination on human adrenal function 2 different ratios were given, 1 pill a day for 20 consecutive days from Day 5 to Day 24 of the ovarian cycle. Medroxyprogesterone acetate, 5 mg, with ethinyl estradiol, 50 mcg, (MAP-5-EE-50) and medroxyprogesterone acetate, 2 mg, with ethinylestradiol, 75 mcg (MAP-2-EE-75) were given to 8 women. Adrenal function was determined before, during, and after therapy and urinary 17-ketosteroids (17-KA), 17-hydroxycorticosteroids (17-OHCS), pregnanediol and pregnanetriol were measured. To stimulate the adrenals iv infusion of .25 mg synthetic ACTH was administered over a period of 6 hours. Stimulation of the pituitary-adrenal axis was done by giving 4.5 gm metopirone in 6 doses in 1 day. In all subjects a definite increase of plasma corticoids was found after 20 days of therapy. In 6 of the 8 cases a definite decrease of urinary 17-OHCS was observed. Pregnanetriol excretion decreased in all cases. Pregnanediol excretion, as determined in the urine throughout the luteal phase of the ovarian cycle, was decreased by both dosages, indicating a blockage of ovulation. Urinary excretion of tetrahydrocortisol and tetrahydrocortisone was decreased in all 5 cases studied. To investigate possible change in cortisol metabolism the percentage of free and conjugated 17-OHCS was determined in 4 cases. Values were unchanged. Half-life of injected cortisol was increased and secretion rate of endogenous cortisol reduced. Added tritiated cortisol in vitro has shown a higher cortisol binding capacity of human plasma after progestinic-estrogenic therapy. Administration of ACTH in 3 cases showed an adrenal response equal to that obtained before treatment, indicating adrenal reserve had been maintained. Hypothalamic-pituitary-adrenal function, as determined with metropione, showed a decrease of urinary adrenal metabolites in all cases. Results show that the 2 doses given block ovulation and that progesterone is not produced by a corpus luteum. The progestinic-estrogenic therapy, in both doses, modified the metabolism of cortisol in the same way as estrogens alone do.
 ...
PMID:Effect of a progestinic-estrogenic combination on human adrenal function. 1230 25